2Zimmerman HJ. Drug-induced liver disease. In: Schiff ER, Sorrell MF, MaddreyWC, eds. Sehiff' s diseases of the liver. New York:Lippincott-Raven, 1998. 973-1004.
3Larrey D, Erlinger S, Krishnasuamy K, et al. Hepatic dysfunction in undernourished patients receiving in soniazid and rifampicin.BaiUieres Clin Gastroenterol, 1998,23:423 -431.
4Turktas H, Unsal M, Tulek N, et al. Hpatotoxicity of antituberculosis therapy (rifampicin, isoniazidand and pyrazinamide ) or viral hepatitis. Tuberc Lung Dis, 1994,75:58-60.
5Miller MS, McCarver DC, BeU DA, et al. Toxic hepatitis with isoniazd and rifampin. Fundam Appl Toxicol, 1999,40 : 1-14.
6Pessyre D, Bentata M, Degott C. Isoniazid-rifampin fulminant hepatitis: a possible consequence of enhancement of isoniazid hepatotoxicity by enzyme induction. Gasteoenterol, 1997, 131:284-292.
7Kaplovitz N. Drug-induced liver disorders: implication for drug development and regulation. Drug Saf,2001,24 :483-490.
8Bissell DM, Gores GJ, Laskin DL, et al. Drug-induced liver injury:mechanisms and test systerms. Hepatology,2001,33 :1009-1013.
9Lewis JH. Drug-induced liver disease. Med Clin North Am,2000,84:1275-1371.
10Anon G. Prevent rifampicin conbined with pyrazinamide induced liver function lesion. Am J Nurs,2001,101:83-86.
